Vir Biotechnology, Inc.
NASDAQ: VIR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marianne De Backer
- Employees
- 408
- Headquarters
- San Francisco, United States
- IPO year
- 2019
- Market cap
- $1.7B
- Website
- https://www.vir.bio
Loading VIR…
Loading profile data…Frequently asked questions about VIR
What does Vir Biotechnology, Inc. (VIR) do?
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating an...
Where does VIR trade?
Vir Biotechnology, Inc. (VIR) trades on the NASDAQ Global Select.
What sector is VIR in?
Vir Biotechnology, Inc. (VIR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vir Biotechnology, Inc.?
Marianne De Backer is the chief executive officer of Vir Biotechnology, Inc. (VIR).
Where is Vir Biotechnology, Inc. headquartered?
Vir Biotechnology, Inc. is headquartered in United States.
Does VIR pay a dividend?
Vir Biotechnology, Inc. (VIR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VIR go public?
Vir Biotechnology, Inc. (VIR) completed its initial public offering in 2019.